Europe’s shares rose on Monday, with defence stocks feeling the benefit amid hopes for higher spending in Europe under Donald ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

"This is a forward-looking statement, mathematically based, and we'll come back with the more detailed guidance come early February 2025," Knudsen said. He said that absolute sales growth last year ...

Ascendis Pharma and Novo Nordisk announced a partnership to develop cardiovascular and metabolic drugs that utilize Ascendis’ ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

He has also worked on technology, energy, and environmental policy issues ... declined as it provided uncertainty on filing its report and delivered weak revenue; Novo Nordisk (NVO) moved higher after ...

European stocks are heading for a lower open Wednesday as global markets focus on the vote count following the U.S.

European stocks reversed earlier gains Wednesday after Donald Trump defeated his Democrat rival Kamala Harris in the U.S.